The results, which were supported by network pharmacology prediction and experimental verification, indicate that the JLSJ prescription can induce cell apoptosis by inhibiting the PI3K/Akt signaling pathway, thereby exerting its anti-lung adenocarcinoma effect. This evidence concerns the gene AKT1 and lung adenocarcinoma.